Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 8.25Amrutanjan Health Care Ltd. demonstrates robust financial health, characterized by exceptional profitability, impressive growth, and a virtually debt-free status. The company's reliance on its own funds for financing assets provides a strong foundation of long-term stability, making it highly resilient. It has consistently expanded its revenues and profits, indicating strong market demand and operational success. Key strengths include outstanding profitability margins and efficient inventory management, which contribute to its healthy cash generation. However, the company shows more moderate performance in how efficiently it uses its total capital to generate sales. While fundamentally very strong, direct shareholder return metrics like earnings and book value per share are average. The future outlook is positive, driven by strong growth momentum and a pristine balance sheet. The main area of observation will be how effectively its large capital base is utilized to drive top-line sales and enhance shareholder value metrics over time.
Health Score : 8.25Amrutanjan Health Care Ltd. demonstrates robust financial health, characterized by exceptional profitability, impressive growth, and a virtually debt-free status. The company's reliance on its own funds for financing assets provides a strong foundation of long-term stability, making it highly resilient. It has consistently expanded its revenues and profits, indicating strong market demand and operational success. Key strengths include outstanding profitability margins and efficient inventory management, which contribute to its healthy cash generation. However, the company shows more moderate performance in how efficiently it uses its total capital to generate sales. While fundamentally very strong, direct shareholder return metrics like earnings and book value per share are average. The future outlook is positive, driven by strong growth momentum and a pristine balance sheet. The main area of observation will be how effectively its large capital base is utilized to drive top-line sales and enhance shareholder value metrics over time.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
24.88
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
70.69
P/B RATIO
13.40
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
8.14
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
4.78
EV/EBITDA RATIO
38.65
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹498.35 as on Sep 1, 2026.
Growth Score : 10.00The company has demonstrated exceptionally strong and broad-based growth. It has consistently expanded its revenues, operating profits, and net income at a very high rate. This comprehensive growth is also reflected in rising earnings for shareholders and an expanding asset base. This performance indicates a highly successful business strategy, strong market demand for its healthcare products, and a very positive trajectory for future expansion and continued profitability.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 34.65 | -3.68 | 2.29 | 17.91 | 12.03 |
| Operating Profit Growth Rate | 38.46 | -5.56 | 29.41 | 9.09 | 29.17 |
| Earnings Per Share (EPS) Growth | 4.52 | 22.77 | 19.72 | 38.24 | |
| Asset Growth Rate | -21.02 | 0 | -3.23 | 3.33 | 12.9 |
| Net Income Growth Rate | 0 | 0 | 20 | 25 | 40 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 6 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 17 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 18 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Amrutanjan Health Care Ltd is a prominent Indian consumer healthcare company specializing in pain management, cold & cough remedies, and women's hygiene products. With over a century-long legacy, it manufactures and markets a diverse portfolio of Ayurvedic and OTC products, maintaining a strong brand presence and widespread distribution across India.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Amrutanjan Health Care Ltd's P/E ratio (TTM) is 24.88, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Amrutanjan Health Care Ltd's P/B ratio is 13.40, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Amrutanjan Health Care Ltd's P/S ratio is 8.14, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Amrutanjan Health Care Ltd's PEG ratio is 4.78.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Amrutanjan Health Care Ltd's EV/EBITDA ratio is 38.65.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Amrutanjan Health Care Ltd's ROE is 19.27%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Amrutanjan Health Care Ltd's ROA is 22.14%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Amrutanjan Health Care Ltd's ROCE is 31%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Amrutanjan Health Care Ltd's operating margin is 17.51%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Amrutanjan Health Care Ltd's net margin is 11.86%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Amrutanjan Health Care Ltd's current ratio is 3.24.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Amrutanjan Health Care Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Amrutanjan Health Care Ltd's interest coverage ratio is 25.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Amrutanjan Health Care Ltd's DPS is ₹1.90.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Amrutanjan Health Care Ltd's EPS is 38.24.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹498.35. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1893
Headquarters: Chennai, Tamil Nadu
Core Offerings: Pain Balms, Cold Rubs & Inhalers, Sanitary Napkins, Body Pain Gels, Fruit Beverages
Stock Listing: NSE (AMRUTANJAN), BSE (590006)
Promoter: Amrutanjan Promoter Group / K. P. Reddy family
1893: Founded by Kasinathuni Nageswara Rao Pantulu, introducing Amrutanjan Pain Balm. 1936: Incorporated as Amrutanjan Limited. 2007: Renamed Amrutanjan Health Care Limited, reflecting strategic diversification into broader consumer healthcare. 2010s onwards: Expanded product portfolio significantly into categories like women's hygiene (Comfy), beverages (Fruitnik), and various OTC segments, leveraging its strong brand equity and distribution network.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Healthcare Products | 85-90% | Higher margins (approx 20-25%) |
| Beverages | 10-15% | Lower margins (approx 5-10%) |
Healthcare Products: Encompasses a wide range of Ayurvedic and allopathic formulations for pain relief (balms, body pain gels, joint pain creams), cold and cough (vapor rub, inhalers), and women's hygiene (Comfy sanitary napkins). The segment benefits from strong brand recognition and an extensive distribution network.
Beverages: Under the 'Fruitnik' and 'Panky' brands, this segment offers fruit-based beverages, aiming to capture the growing demand for healthy and convenient drink options, primarily distributed in the South Indian market.
S. Sambhu Prasad (Chairman & Managing Director): A member of the promoter family, he has been instrumental in shaping the company's strategic direction and diversification efforts over several decades, leading its transformation into a modern healthcare entity.
Bonus Issue: 1:1 in 2008. Bonus Issue: 1:2 in 2018.
The Amrutanjan Health Care Ltd share price today is ₹498.35 on NSE (AMRUTANJAN), as of 26 Sept 2026.
As of 25 Sept 2026, Amrutanjan Health Care Ltd share price is ₹498.35, with previous close ₹498.35. Today's range is ₹498.35 to ₹498.35. The 52-week range is ₹476.50 to ₹705.45.
As of today, Amrutanjan Health Care Ltd's market cap is ₹1,440.23 crore (Small Cap).
Amrutanjan Health Care Ltd's current P/E ratio is 24.88, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
Amrutanjan Health Care Ltd's current P/B ratio is 13.40.
Amrutanjan Health Care Ltd's current dividend yield is 0.38%. Last dividend of ₹0.50 per share was declared on 09-Feb-2024.
Amrutanjan Health Care Ltd's EPS (TTM) is ₹38.24.
Amrutanjan Health Care Ltd is a prominent Indian consumer healthcare company specializing in pain management, cold & cough remedies, and women's hygiene products. With over a century-long legacy, it manufactures and markets a diverse portfolio of Ayurvedic and OTC products, maintaining a strong brand presence and widespread distribution across India.
Amrutanjan Health Care Ltd is promoted by Amrutanjan Promoter Group / K. P. Reddy family, holding 46.52% as of 25 Sept 2026.
Amrutanjan Health Care Ltd is listed on NSE (AMRUTANJAN) and BSE (590006). Its next quarterly results are expected on August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)
Capital Expenditures (CapEx)
